Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Citi
Argus Health
QuintilesIMS
Deloitte
Colorcon
Cantor Fitzgerald
Boehringer Ingelheim

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090313

« Back to Dashboard

NDA 090313 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Apnar Pharma Lp, Belcher Pharms Llc, Citrusphrma, Cmp Pharma Inc, Eci Pharms Llc, Epic Pharma Llc, Nuvo Pharm Inc, Wockhardt, Morton Grove, Paddock Llc, Roxane, and West-ward Pharms Int, and is included in twelve NDAs. It is available from eight suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.

The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred and twenty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
Summary for 090313
Tradename:SODIUM POLYSTYRENE SULFONATE
Applicant:Eci Pharms Llc
Ingredient:sodium polystyrene sulfonate
Patents:0
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 090313
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SODIUM POLYSTYRENE SULFONATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 090313 ANDA ECI Pharmaceuticals, LLC 51293-831 N 51293-831-97

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORAL, RECTALStrength453.6GM/BOT
Approval Date:Dec 21, 2011TE:AARLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Moodys
Covington
Cipla
AstraZeneca
US Department of Justice
Fuji
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.